Taysha Gene Therapies, Inc. announced that it entered into a Trinity Term Loan Agreement for aggregate principal amount of $40 million on November 13, 2023. The transaction will include participation from new lender, Trinity Capital Inc. The interest rate applicable to the Trinity Term Loans is the greater of prime rate plus 4.50% or 12.75% per annum. The Trinity Term Loans are interest only from the Trinity closing date through 36 months from the Trinity closing date, which may be extended to 48 months from the Trinity closing date upon the satisfaction of certain milestones set forth in the Trinity Term Loan Agreement, after which we are required to pay equal monthly installments of principal through November 13, 2028, or the maturity date.

The Trinity term loans may be prepaid in full (i) from the Trinity closing date through November 13, 2024, with payment of a 3.00% prepayment premium, (ii) from November 13, 2024 through November 13, 2025, with payment of a 2% prepayment premium, and (iii) from November 13, 2025 through, but excluding, the Maturity Date, with payment of a 1% prepayment premium. Upon repayment in full of the Trinity Term Loans, company will pay to Trinity an end of term payment equal to 5.00% of the original principal amount of the Trinity Term Loans.